NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,413.79 +206.66 (+1.14%) CRUDE OIL
79.22 +0.27 (+0.34%) GOLD FUTURES
2,312.10 +2.50 (+0.11%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,644.42 +1,910.64 (+4.18%)
Recce Pharmaceuticals Ltd (RCE.AX)
| Previous close | 0.6400 |
| Open | 0.6600 |
| Bid | 0.6350 x 55200 |
| Ask | 0.6450 x 1644700 |
| Day's range | 0.6400 - 0.6600 |
| 52-week range | 0.4100 - 0.7772 |
| Volume | |
| Avg. volume | 170,672 |
| Market cap | 131.549M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects, with dosing to start in near weeksR327 dosed at 3,000mg has successfully been tested at various infusion times (15, 20, 30, 45 minutes, and 1 hour)Minimum Inhibitory Concentration (MIC) activity identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuti
- GlobeNewswire
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP standards in support of current and anticipated clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) SYDNEY, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic an
- GlobeNewswire
Recce Pharmaceuticals Provides Business Update
Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens dur
